Literature DB >> 16854067

Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin.

Madan Katragadda1, Paola Magotti, Georgia Sfyroera, John D Lambris.   

Abstract

Tryptophans at positions 4 and 7 of compstatin, a peptide complement inhibitor, are crucial for its interaction with C3. However, the nature of their involvement has not been studied to date. Here we investigate the molecular forces involved in the C3-compstatin interactions, mediated by aromatic residues, by incorporating in these two positions various tryptophan analogues (5-methyltryptophan, 5-fluorotryptophan, 1-methyltryptophan, and 2-naphthylalanine) and assessing the resulting peptides for activity by enzyme-linked immunosorbent assay (ELISA) and binding by isothermal titration calorimetry (ITC). Of all the compstatin analogues, peptides containing 1-methyltryptophan at position 4 exhibited the highest binding affinity (Kd = 15 nM) and activity (IC50 = 0.205 microM), followed by a peptide containing 5-fluorotryptophan at position 7. Our observations suggest that hydrophobic interactions involving residues at position 4 and the hydrogen bond initiated by the indole nitrogen are primarily responsible and crucial for the increase in activity. These findings have important implications for the design of clinically useful complement inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16854067     DOI: 10.1021/jm0603419

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  57 in total

1.  Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.

Authors:  Ole-Lars Brekke; Bernt Christian Hellerud; Dorte Christiansen; Hilde Fure; Albert Castellheim; Erik Waage Nielsen; Anne Pharo; Julie Katrine Lindstad; Grethe Bergseth; Graham Leslie; John D Lambris; Petter Brandtzaeg; Tom Eirik Mollnes
Journal:  Mol Immunol       Date:  2011-08-11       Impact factor: 4.407

2.  A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatin.

Authors:  Chandrika Mulakala; John D Lambris; Yiannis Kaznessis
Journal:  Bioorg Med Chem       Date:  2006-12-13       Impact factor: 3.641

Review 3.  Complement-targeted therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

Review 4.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

5.  Stages of meningococcal sepsis simulated in vitro, with emphasis on complement and Toll-like receptor activation.

Authors:  Bernt Christian Hellerud; Jørgen Stenvik; Terje Espevik; John D Lambris; Tom Eirik Mollnes; Petter Brandtzaeg
Journal:  Infect Immun       Date:  2008-06-30       Impact factor: 3.441

6.  A new generation of potent complement inhibitors of the Compstatin family.

Authors:  Aliana López de Victoria; Ronald D Gorham; Meghan L Bellows-Peterson; Jun Ling; David D Lo; Christodoulos A Floudas; Dimitrios Morikis
Journal:  Chem Biol Drug Des       Date:  2011-04-26       Impact factor: 2.817

7.  Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation.

Authors:  Masafumi Goto; Jenny Tjernberg; Denis Dufrane; Graciela Elgue; Daniel Brandhorst; Kristina Nilsson Ekdahl; Heidi Brandhorst; Lars Wennberg; Yoshimochi Kurokawa; Susumu Satomi; John D Lambris; Pierre Gianello; Olle Korsgren; Bo Nilsson
Journal:  Xenotransplantation       Date:  2008 Jul-Aug       Impact factor: 3.907

8.  Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry.

Authors:  Michael C Schuster; Daniel Ricklin; Krisztián Papp; Kathleen S Molnar; Stephen J Coales; Yoshitomo Hamuro; Georgia Sfyroera; Hui Chen; Michael S Winters; John D Lambris
Journal:  Mol Immunol       Date:  2008-05-05       Impact factor: 4.407

9.  Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

Authors:  Yvonne Klapper; Osama A Hamad; Yuji Teramura; Gero Leneweit; G Ulrich Nienhaus; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Biomaterials       Date:  2014-01-23       Impact factor: 12.479

10.  Cell membrane modification for rapid display of bi-functional peptides: a novel approach to reduce complement activation.

Authors:  Ledia Goga; Gustavo Perez-Abadia; Sathnur B Pushpakumar; Daniel Cramer; Jun Yan; Nathan Todnem; Gary Anderson; Chirag Soni; John Barker; Claudio Maldonado
Journal:  Open Cardiovasc Med J       Date:  2010-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.